SVF
Level D· Preclinical EvidenceAnimal Study

Evaluating the Homing Potential of Adipose-Derived Stromal Cells Following Dorsal Subcutaneous Injection in a Rat Fat Graft Model.

Ho CY., Tsai TH., Chang DH., Chen YS., Wu SC., Lin FH.

Animal Study on Facial Rejuvenation, published in Aesthetic Plast Surg (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Aesthetic Plast Surg (2026)
Country
United States
Reported sample size
—
PMID
41071366
DOI
10.1007/s00266-025-05275-z

Abstract (original English)

Cell-assisted lipotransfer is a fat-grafting technique that uses adipose tissue from lipoaspirates mixed with adipose-derived stromal cells (ASCs) to enhance fat graft survival. Intravenously injected ASCs migrate to the fat graft site via circulatory system; however, a large portion of circulatory ASCs can get trapped in the lungs, reducing the amount of available ASCs for fat graft. The molecular and cellular mechanisms modulating ASC homing remain unclear. We aimed to investigate the migration and infiltration of ASCs to adjacent fat graft when injected subcutaneously. A fat graft was implanted on the dorsal side of Sprague-Dawley rats without genetic modification. Green fluorescent protein (GFP)-ASCs were harvested from genetically engineered Sprague-Dawley rats and injected subcutaneously cephalically away from the fat graft at 0, 1, and 2 cm. The migration and fate of the injected GFP-ASCs in relation to fat grafts were monitored using an in vivo imaging system for 4 weeks, and GFP fluorescence in fat graft was examined under a microscope. Cell migration was observed at both 1 and 2 cm from the fat graft. However, ASC infiltration to the fat graft was greater at a distance of 1 cm away from the graft than at 0 and 2 cm. ASC migration into fat grafts was observed after subcutaneous injection. ASCs injected at a distance of 1 cm showed positive retention rates ASCs those mi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsRats, Sprague-DawleyRatsCell MovementInjections, SubcutaneousAdipose TissueGraft SurvivalStromal CellsMaleModels, Animal
Systemic / IVFacial Rejuvenation
View on PubMedDOI

Related research